Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1 Omar Abdel-Razek, MD, Singh N. Sadananda, PhD, Xuan Li, MSc, Lubomira Cermakova, MSc, Jiri Frohlich, MD, FRCPC, Liam R. Brunham, MD, PhD, FRCPC Journal of Clinical Lipidology Volume 12, Issue 1, Pages 116-121 (January 2018) DOI: 10.1016/j.jacl.2017.10.010 Copyright © 2017 National Lipid Association Terms and Conditions
Figure 1 Prevalence of clinical or subclinical atherosclerotic cardiovascular disease (ASCVD) in individuals with damaging mutations in ABCA1 or APOA1. ∗P < .05. Journal of Clinical Lipidology 2018 12, 116-121DOI: (10.1016/j.jacl.2017.10.010) Copyright © 2017 National Lipid Association Terms and Conditions
Figure 2 Cholesterol efflux capacity (CEC) in individuals with damaging mutations in ABCA1 or APOA1. (A) Cholesterol efflux capacity. Results are presented as mean ± standard deviation. (B) Correlation between cholesterol efflux capacity and HDL-C levels. (C) Correlation between cholesterol efflux capacity and apoA-I levels. ∗P < .05. HDL-C, high-density lipoprotein cholesterol. Journal of Clinical Lipidology 2018 12, 116-121DOI: (10.1016/j.jacl.2017.10.010) Copyright © 2017 National Lipid Association Terms and Conditions